Hmr59 Emerging Drug Insight And Market Forecast

“HMR59- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Geographic Atrophy in 7 Major Markets. A detailed picture of the HMR59 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary

CD59 is a protective protein that is normally found on the plasma membrane of cells. CD59 protects cells from a natural inflammatory cascade in the body called complement that acts as a part of the body’s nonspecific immune response. An overactivity of complement is felt to be the cause of macular degeneration. Studies have also shown that patients with AMD have less CD59 present in the retina to protect their cells from damage caused by complement. Hemera’s gene therapy that is under FDA approved clinical testing to treat both the dry and wet forms of AMD is called HMR59. HMR59 injected in the eye increases the ability of retina cells to make a soluble form of CD59 called sCD59. The soluble CD59 circulates within the retina to block complement from further damaging the retina.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around HMR59.
  • The report contains forecasted sales for HMR59 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Geographic Atrophy.
  • The report also features the SWOT analysis with analyst insights and key findings of HMR59.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HMR59 Analytical Perspective by DelveInsight

  • In-depth HMR59 Market Assessment

This report provides a detailed market assessment of HMR59 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.


  • HMR59 Clinical Assessment

The report provides the clinical trials information of HMR59 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Geographic Atrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence HMR59 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Geographic Atrophy are giving market competition to HMR59 and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of HMR59.
  • Our in-depth analysis of the forecasted sales data of HMR59 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HMR59. 

Key Questions

  • Which company is developing HMR59 along with the phase of the clinical study?
  • What is the technology utilized in the development of HMR59?
  • What is the product type, route of administration and mechanism of action of HMR59?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HMR59 development?
  • What are the key designations that have been granted to HMR59?
  • What is the forecasted market scenario of HMR59?
  • What is the history of HMR59 and what is its future?
  • What is the forecasted sales of HMR59 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to HMR59?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

 

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Table

 Table 1 HMR59, Description

Table 2 HMR59, Clinical Trial Description

Table 3 HMR59, 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figure

 Figure 1 The Development Timeline of HMR59

Figure 2 Patent Details, HMR59

Figure 3 HMR59, 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 HMR59, US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 HMR59, EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 HMR59, Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • "HMR59 Pipeline
  • HMR59 DMD
  • HMR59 MOA
  • HMR59 Mechanism of action
  • HMR59 Duchenne Muscular Dystrophy
  • HMR59 launch date
  • HMR59 US Share
  • HMR59 launch year
  • HMR59 Market Share
  • HMR59 company name "

Forward to Friend

Need A Quote